{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(4)"],"submitter":["Akinosoglou K"],"pubmed_abstract":["(1) Background: It is well-established that coronavirus disease-2019 (COVID-19) is highly pro-inflammatory, leading to activation of the coagulation cascade. COVID-19-induced hypercoagulability is associated with adverse outcomes and mortality. Current guidelines recommend that hospitalized COVID-19 patients should receive pharmacological prophylaxis against venous thromboembolism (VTE). (2) INTERACT is a retrospective, phase IV, observational cohort study aiming to evaluate the overall clinical effectiveness and safety of a higher than conventionally used prophylactic dose of anticoagulation with tinzaparin administered for VTE prevention in non-critically ill COVID-19 patients with moderate disease severity. (3) Results: A total of 705 patients from 13 hospitals in Greece participated in"],"journal":["Viruses"],"pagination":["767"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9027745"],"repository":["biostudies-literature"],"pubmed_title":["Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study."],"pmcid":["PMC9027745"],"pubmed_authors":["Mitsianis A","Akinosoglou K","Xarras P","On Behalf Of The Interact Study Group","Chatzistamati A","Savvanis S","Milionis H","Golemi F","Randou E","Kaiafa G","Panagopoulos P","Samaras V","Papazoglou D","Efraimidis G","Triantafyllidis C","Papanikolaou IC","Konstantinidou A","Pavlaki M","Savopoulos C","Vadala C","Markatis E","Varela K","Liontos A","Pouliakis A","Dimakopoulou V"],"additional_accession":[]},"is_claimable":false,"name":"Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study.","description":"(1) Background: It is well-established that coronavirus disease-2019 (COVID-19) is highly pro-inflammatory, leading to activation of the coagulation cascade. COVID-19-induced hypercoagulability is associated with adverse outcomes and mortality. Current guidelines recommend that hospitalized COVID-19 patients should receive pharmacological prophylaxis against venous thromboembolism (VTE). (2) INTERACT is a retrospective, phase IV, observational cohort study aiming to evaluate the overall clinical effectiveness and safety of a higher than conventionally used prophylactic dose of anticoagulation with tinzaparin administered for VTE prevention in non-critically ill COVID-19 patients with moderate disease severity. (3) Results: A total of 705 patients from 13 hospitals in Greece participated in","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-22T10:59:05.678Z","creation":"2024-11-19T21:20:53.545Z"},"accession":"S-EPMC9027745","cross_references":{"pubmed":["35458497"],"doi":["10.3390/v14040767"]}}